TKM-100802 for Injection + Placebo
Phase 1Terminated 0 watching 0 views this week๐ค Quiet
28
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ebola Virus Infection
Conditions
Ebola Virus Infection
Trial Timeline
Jan 1, 2014 โ Jul 1, 2015
NCT ID
NCT02041715About TKM-100802 for Injection + Placebo
TKM-100802 for Injection + Placebo is a phase 1 stage product being developed by Arbutus Biopharma for Ebola Virus Infection. The current trial status is terminated. This product is registered under clinical trial identifier NCT02041715. Target conditions include Ebola Virus Infection.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02041715 | Phase 1 | Terminated |
Competing Products
20 competing products in Ebola Virus Infection